F.6	Human insulin – cartridges and prefilled pens 100U/mL– EML and EMLc	
Draft recommendation		☐ Recommended
		☑ Not recommended
		Justification:
		What is considered as essential is the availability of the human insulin itself and the proposed device will not likely to improve insulin availability and access in many countries. Although the device is believed to improve the experience of the insulin user yet the improvement is not of high clinical importance and not based on high level of evidences.
Does the proposed medicine address a relevant public health need?		⊠ Yes
		□No
		☐ Not applicable
		Comments:
		Diabetes is a major public health problem. Insulin is lifesaving in type 1 diabetes and may be required in type 2 diabetes. However what is being proposed in the application is the packaging of the insulin.
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence		☐ Yes
		⊠ No
		☐ Not applicable
		Comments:
	g the review process)	Certainty of the evidences are low and the importance of the effect is small
Does adequate evidence exist for the safety/harms associated with the proposed medicine?		⊠ Yes
		□No
		☐ Not applicable
(this may be evidence included in the application, and/or additional evidence identified during the review process)		Comments: No harm is reported.
		Sommer de la companya
Are there any	adverse effects of	□ Yes
concern, or th	at may require special	⊠ No
monitoring?		□ Not applicable
		Comments:

24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

Are there any special requirements for the safe, effective and appropriate use of the medicines? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	 Yes No Not applicable Comments: Considered as easier and more convenient than the existing device.
Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?	 ✓ Yes ☐ No ☐ Not applicable Comments: The cost is higher than the existing device
Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	☐ Yes ☑ No ☐ Not applicable Comments:
Is the proposed medicine recommended for use in a current WHO guideline? (refer to: https://www.who.int/publications/whoguidelines)	 ☐ Yes ☒ No ☐ Not applicable Comments: Current guideline did not specifically state about any preferred device.